1. Home
  2. ALLO vs ACRS Comparison

ALLO vs ACRS Comparison

Compare ALLO & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$0.76

Market Cap

452.6M

Sector

Health Care

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

SELL

Current Price

$3.34

Market Cap

529.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ALLO
ACRS
Founded
2017
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
452.6M
529.9M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
ALLO
ACRS
Price
$0.76
$3.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
12
Target Price
$9.00
★ $10.50
AVG Volume (30 Days)
★ 11.2M
2.7M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
34.09
★ 69.01
EPS
N/A
★ N/A
Revenue
N/A
★ $1,683,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$72.02
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.74
$2.34
52 Week High
$4.46
$6.60

Technical Indicators

Market Signals
Indicator
ALLO
ACRS
Relative Strength Index (RSI) 21.26 37.00
Support Level N/A $3.24
Resistance Level $2.25 $3.44
Average True Range (ATR) 0.10 0.28
MACD -0.02 0.01
Stochastic Oscillator 0.42 9.38

Price Performance

Historical Comparison
ALLO
ACRS

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: